Paper Details

  1. Home
  2. Paper Details

Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.

Author: BarrettJeffrey S, DouglasSteven D, EvansDwight L, KimDeborah, PappaVasiliki, SpitsinSergei, TaylorDeanne, TebasPablo

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluates the safety, pharmacokinetics, and anti-inflammatory properties of aprepitant, an NK1R antagonist, in HIV-positive individuals receiving cART. Aprepitant is a potential therapeutic agent due to its anti-HIV and anti-inflammatory properties.
Paper Details　
Original Abstract of the Article :
HIV-infected individuals, even well controlled with combined antiretroviral therapy (cART), have systemic inflammation and comorbidities. Substance P (SP) is an undecapeptide, which mediates neurotransmission and inflammation through its cognate neurokinin 1 receptor (NK1R). Plasma SP levels are ele...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841871/

データ提供：米国国立医学図書館（NLM）

HIV-Infected Individuals: Navigating a Desert of Inflammation

HIV-infected individuals, even those well-controlled with combined antiretroviral therapy (cART), often face a challenging desert landscape of inflammation and comorbidities. This research explores the potential of aprepitant, an NK1R antagonist, as a therapeutic oasis for HIV-infected individuals. The researchers evaluated the safety, pharmacokinetics, and anti-inflammatory properties of aprepitant in HIV-positive individuals receiving cART. Their findings highlight the potential of aprepitant as a valuable tool for reducing inflammation and improving overall health in HIV-infected individuals. This research is like a search for a hidden oasis in the desert, seeking to alleviate the burdens of inflammation and improve the lives of those living with HIV.

A Beacon of Hope: Aprepitant's Promise

This research underscores the potential of aprepitant, an NK1R antagonist, as a therapeutic oasis for HIV-infected individuals. The study's findings suggest that aprepitant may have anti-inflammatory effects and could play a role in managing the chronic inflammation often associated with HIV infection. This is like discovering a hidden spring in the desert, offering a source of relief from the relentless inflammation that can accompany HIV infection.

Finding a Path to Well-being: Managing Inflammation in HIV

This research emphasizes the importance of addressing inflammation in HIV-infected individuals. By exploring the potential of aprepitant and other anti-inflammatory therapies, healthcare providers can work to improve the overall health and well-being of their patients. This research is like a roadmap, guiding healthcare providers towards a more effective and comprehensive approach to managing HIV infection and its associated complications.

Dr. Camel's Conclusion

This research provides valuable insights into the potential of aprepitant as a therapeutic oasis for HIV-infected individuals. By targeting the NK1R and potentially reducing inflammation, aprepitant may offer a new path towards improved health and well-being for those living with HIV. This research is like a compass, guiding us towards a better understanding of the complexities of HIV infection and its management.

Date :
  1. Date Completed 2019-07-29
  2. Date Revised 2020-03-06
Further Info :

Pubmed ID

28978797

DOI: Digital Object Identifier

PMC5841871

Related Literature

Article Analysis
・Effects of aprepitant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.